{"name":"IMPAX LABS","slug":"impax-labs","ticker":"","exchange":"","domain":"impaxlabs.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1973-01-01","label":"Pyrilamine first approved","drug":"Pyrilamine","drugSlug":"mepyramine","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Albenza first approved","drug":"Albenza","drugSlug":"albendazole","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Albenza","genericName":"ALBENDAZOLE","slug":"albendazole","indication":"Parenchymal neurocysticercosis","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pyrilamine","genericName":"mepyramine","slug":"mepyramine","indication":"Allergic conjunctivitis","status":"marketed"}]}],"pipeline":[{"name":"Albenza","genericName":"ALBENDAZOLE","slug":"albendazole","phase":"marketed","mechanism":"Albenza works by binding to tubulin in the parasite's microtubules, disrupting their function and ultimately leading to the parasite's death.","indications":["Parenchymal neurocysticercosis","Cystic hydatid disease"],"catalyst":""},{"name":"Pyrilamine","genericName":"mepyramine","slug":"mepyramine","phase":"marketed","mechanism":"Histamine H1 receptor","indications":["Allergic conjunctivitis","Allergic rhinitis","Common cold","Dermatographic urticaria","Dysmenorrhea"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}